We are live on ! Find out more
OAM

Oxford Asset Management Portfolio holdings

AUM $232M
1-Year Est. Return 31%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+31%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$3.85B
AUM Growth
-$949M
Cap. Flow
-$393M
Cap. Flow %
-10.22%
Top 10 Hldgs %
10.07%
Holding
2,323
New
652
Increased
471
Reduced
539
Closed
577

Sector Composition

Rank Sector Weight
1 Technology 15.44%
2 Consumer Discretionary 14.53%
3 Healthcare 13.43%
4 Industrials 13.16%
5 Financials 12.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VIA
1626
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
$121K ﹤0.01%
+3,254
New +$135K
RAD
1627
DELISTED
Rite Aid Corporation
RAD
$120K ﹤0.01%
+8,475
New +$179K
HLX icon
1628
Helix Energy Solutions
HLX
$1.41B
$119K ﹤0.01%
+22,042
New +$180K
BFIIW
1629
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
$119K ﹤0.01%
411,759
AMKR icon
1630
Amkor Technology
AMKR
$13.7B
$117K ﹤0.01%
17,794
-191,331
-91% -$1.26M
CVM icon
1631
CEL-SCI Corp
CVM
$30.1M
$117K ﹤0.01%
+1,361
New +$131K
TGTX icon
1632
TG Therapeutics
TGTX
$7.62B
$117K ﹤0.01%
+28,469
New +$141K
KDNY
1633
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$117K ﹤0.01%
+8,872
New +$177K
YGYI
1634
DELISTED
Youngevity International, Inc Common Stock
YGYI
$115K ﹤0.01%
+20,152
New +$156K
EGY icon
1635
Vaalco Energy
EGY
$594M
$114K ﹤0.01%
77,439
-131,586
-63% -$251K
TNXP icon
1636
Tonix Pharmaceuticals
TNXP
$192M
0
CHS
1637
DELISTED
Chicos FAS, Inc.
CHS
$112K ﹤0.01%
19,854
-508,592
-96% -$3.54M
XONE
1638
DELISTED
The ExOne Company
XONE
$112K ﹤0.01%
+16,883
New +$136K
RBZ
1639
DELISTED
Reebonz Holding Limited Ordinary Shares
RBZ
$112K ﹤0.01%
+6,740
New +$140K
SBBP
1640
DELISTED
Strongbridge Biopharma plc.
SBBP
$110K ﹤0.01%
+24,593
New +$120K
EDTXW
1641
DELISTED
EdtechX Holdings Acquisition Corp. Warrant
EDTXW
$110K ﹤0.01%
+315,000
New +$124K
CMSSW
1642
DELISTED
CM Seven Star Acquisition Corporation Warrant
CMSSW
$110K ﹤0.01%
440,000
VTVT icon
1643
vTv Therapeutics
VTVT
$139M
$106K ﹤0.01%
+1,004
New +$92.9K
LCTX icon
1644
Lineage Cell Therapeutics
LCTX
$278M
$105K ﹤0.01%
+115,409
New +$177K
BLNK icon
1645
Blink Charging
BLNK
$87.9M
$103K ﹤0.01%
+59,705
New +$130K
OTRK
1646
DELISTED
Ontrak
OTRK
$103K ﹤0.01%
+122
New +$110K
FTNW
1647
DELISTED
FTE Networks, Inc.
FTNW
$103K ﹤0.01%
+43,980
New +$298K
GERN icon
1648
Geron
GERN
$949M
$102K ﹤0.01%
+102,148
New +$155K
TRIL
1649
DELISTED
Trillium Therapeutics Inc.
TRIL
$98K ﹤0.01%
+57,055
New +$171K
NG icon
1650
NovaGold Resources
NG
$3.33B
$96K ﹤0.01%
+24,416
New +$96.4K

Similar funds

Oxford Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Oxford Asset Management held 2,323 positions worth $3.85B, down 20% from $4.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Oxford Asset Management withdrew a net $393M in Q4 2018, closing 577 positions and reducing 539 holdings. Its most notable exit was Envision Healthcare Holdings Inc, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Oxford Asset Management opened a new position in Athenahealth, Inc. worth $69.9M.

  • Oxford Asset Management's largest Q4 2018 buy was Athenahealth, Inc.: 530,000 shares worth $69.9M.
  • Oxford Asset Management added most to Integrated Device Technology I in Q4 2018, an estimated $34.6M increase.
  • Oxford Asset Management's biggest Q4 2018 reduction was GE Aerospace, cutting an estimated $18.1M.
  • Oxford Asset Management fully exited Envision Healthcare Holdings Inc in Q4 2018, selling an estimated $105M.
  • Oxford Asset Management's ten largest holdings make up 10% of its $3.85B portfolio in Q4 2018.
  • Oxford Asset Management opened 652 new positions and closed 577 in Q4 2018.
  • Oxford Asset Management's portfolio value fell 20% quarter-over-quarter to $3.85B.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.